Tracking systemic therapy resistance of lung and colorectal cancer through targeted NGS analysis of genetic and epigenetic variants in liquid biopsies.
The TRACEPIGEN project focuses on the analysis of circulating cell-free DNA (cfDNA) to study the evolution of genetic and epigenetic landscape in response to systemic therapy to identify biomarkers for dynamic monitoring during cancer progression.
TRACEPIGEN brings together a group of enthusiastic young researchers with complementary skills to work on an ambitious project incorporating cutting-edge methodology with an exciting clinically relevant research question.
Research support
This research was supported by the Science Fund of the Republic of Serbia, PROMIS, #6060876, TRACEPIGEN